The chief executive of Botanical Solution Inc. (BSI) speaks about the development of QS-21 adjuvant for vaccines from Quillaja saponaria trees grown in BSI labs
What are some key supply considerations that sponsors need to keep in mind when planning a DCT? What should they look out for when choosing a supply partner?
He talks to us about key developments in the inhalation industry and how the formation of a leading global CDMO can provide support in navigating these changes.
Worth $14 million, entails providing project management and administrative oversight as the IRB of record for Biorepository Protocol and NIAID studies.